RxDoctor Payments Data

William Devito, DO

Family Medicine · Prescott, AZNPI 1073559738

Payments from drug & device makers

$601in general payments, 2019–2025

Across 30 payments — averaging $20.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$205
  • Pfizer$178
  • Astellas Pharma US Inc$100
  • AstraZeneca$93
  • Boston Scientific$26

What the payments were for

  • Food & beverage$50183%
  • Education$10017%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen11$205
Pfizer10$178
Astellas Pharma US Inc1$100
AstraZeneca7$93
Boston Scientific1$26

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$601 in reported general payments places this provider in the 60th percentile of 2,099 family medicine providers in Arizona.

See all family medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$421,311
Medicare patients
1,388
Services billed
5,228

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban230$217,492
OzempicSemaglutide133$151,183
JardianceEmpagliflozin101$143,655
JanuviaSitagliptin Phosphate72$75,906
MyrbetriqMirabegron69$61,325
XareltoRivaroxaban38$58,421
TrulicityDulaglutide29$54,613
LinzessLinaclotide27$21,527
Repatha SureclickEvolocumab19$19,061
Arnuity ElliptaFluticasone Furoate32$16,842
Spiriva HandihalerTiotropium Bromide22$15,645
Levothyroxine Sodium1,332$12,493
FarxigaDapagliflozin Propanediol14$11,720
Fluticasone-SalmeterolFluticasone Propion/Salmeterol74$10,904
Atorvastatin Calcium1,199$10,871

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$178$217,492230 claims
Astellas Pharma US IncMyrbetriq$100$61,32569 claims
AstraZenecaFarxiga, Symbicort$93$19,97437 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,099 family medicine providers in Arizona.

Other family medicine in Prescott

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →